Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Adipose tissue-derived mesenchymal stem cell extracellular vesicles enhance amyloid-beta degradation in an in vitro Alzheimer's model.

Aydemi̇r M., Gacar G., Halbutoğullari ZS., Duruksu G., Öztürk A., Altuntaş C.

Laboratory Study on Neuroinflammation, published in Tissue Cell (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Tissue Cell (2025)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
40651085
DOI
10.1016/j.tice.2025.103035

Abstract (original English)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder lacking effective treatment. Mesenchymal stem cells (MSCs) and extracellular vesicles (EVs) have shown promise in degrading amyloid beta (Aβ) plaques due to their low immunogenicity and ability to mediate intercellular communication. This study investigates the therapeutic potential of EVs derived from human adipose tissue MSCs (hAT-MSCs) and preconditioned human adipose tissue MSCs in an in vitro AD model. MSCs characterized by flow cytometry and differentiation assays. hAT-MSCs stimulated with hydrogen peroxide (H₂O₂) or a cytokine complex (CC; TNF-α, IL-1β, IFN-γ). EVs were isolated via ultracentrifugation and analyzed by electron microscopy and Zetasizer. An in vitro AD model was established using neural-differentiated SH-SY5Y cells treated with Aβ peptides. Differentiation and Aβ degradation were assessed using immunocytochemistry, qRT-PCR, and ELISA. EVs derived from cytokine complex stimulated hAT-MSCs significantly reduced Aβ plaque size and intensity compared to EVs from unstimulated or H₂O₂-stimulated cells. When immunocytochemistry images were analyzed using ImageJ, Aβ levels were found to be highest in the Alzheimer's group and lowest in the CC-EV group. According to ELISA analyses, no significant difference was observed between the Alzheimer's model (a1) and the hAT-MSC-EVs (a3) groups, whereas bo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMesenchymal Stem CellsAlzheimer DiseaseExtracellular VesiclesAmyloid beta-PeptidesAdipose TissueCell DifferentiationHydrogen PeroxideCell Line, TumorModels, Biological

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research